Navigation Links
Schering-Plough Completes Acquisition of Organon BioSciences
Date:11/19/2007

Combination Expands Human Health Business, Creates a Global Leader in Animal Health and Strengthens Product Pipeline, Adding Five Phase III

Projects

KENILWORTH, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

"By bringing together complementary businesses, we will be growing even stronger and even better in our people, products and science," said Fred Hassan, chairman and chief executive officer, Schering-Plough Corporation. "The promise of this combination is profound. We will be working hard to realize that promise -- for our customers, for the patients, for our other stakeholders and for our shareowners."

Organon BioSciences is comprised primarily of Organon, a human health business, and Intervet, an animal health business. It also includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.

Hassan said, "Through this combination we create a powerful science and technology platform. We expand and strengthen Schering-Plough's late-stage Rx pipeline with five additional promising Phase III compounds. We acquire a robust biologics manufacturing capability that is an excellent match for our earlier-stage biologics projects.

"With Organon, we expand into two
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
6. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Carrington Completes $8 Million Financing
9. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
10. New Brunswick Scientific Completes Merger Transaction with Eppendorf
11. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... - Elsevier, a world-leading provider of scientific, technical and ... of a recent study in Reproductive BioMedicine ... that those with an abnormal chromosomal composition can be ... to blastocysts, thereby classifying the risk of genetic abnormality ... group has undertaken a retrospective study, using their predictive ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... , TORONTO , Jan. 28 ... company developing innovative immune-based biologics, today announced that Dr. ... Directors as an independent director. Trillium Chairman Dr. ... to welcome such an experienced biotech executive as Dr. ...
... ... DNA (or RNA). To help illustrate the basics of DNA origami, Harvard’s Wyss Institute has ... simple, abstract representation of a DNA molecule and then allowing it to self assemble. ... Boston, Mass. (PRWEB) January 28, ...
... , PRINCETON, N.J. , Jan. 27 Covance Inc. ... ended December 31, 2009 of $0.64 per diluted ... a GAAP basis, inclusive of $0.10 per share in gains ... tax resolutions in the third quarter.  Excluding the gains on sales and ...
Cached Biology Technology:Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 2Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 3Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:5/17/2013)... interaction of a group of proteins in the brain ... a new target that could increase cell survival. , ... of Biochemistry and published in the EMBO journal ... lead to new therapies for stroke and other brain ... the team which identified a protein, known as SUMO, ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... Reportlinker.com announces that a new ... Biometrics: Technologies and Global Markets ... AND OBJECTIVESThis report studies the global as well as ... purpose of locating newer markets and expanding the present ...
... project using cameras mounted on unmanned aircraft flying over the ... declining sea ice and using the same aerial photos to ... The project is the first to use aircraft to monitor ... observers at risk, said Elizabeth Weatherhead of the University of ...
... reactions that asthmatics suffer towards a common mould have ... mould growing in their own lungs. The research ... has been published in the December 2010 issue of ... Medicine . The team based in the Institute ...
Cached Biology News:Reportlinker Adds Biometrics: Technologies and Global Markets 2Reportlinker Adds Biometrics: Technologies and Global Markets 3Reportlinker Adds Biometrics: Technologies and Global Markets 4Reportlinker Adds Biometrics: Technologies and Global Markets 5Reportlinker Adds Biometrics: Technologies and Global Markets 6Reportlinker Adds Biometrics: Technologies and Global Markets 7Reportlinker Adds Biometrics: Technologies and Global Markets 8Reportlinker Adds Biometrics: Technologies and Global Markets 9Reportlinker Adds Biometrics: Technologies and Global Markets 10Reportlinker Adds Biometrics: Technologies and Global Markets 11Reportlinker Adds Biometrics: Technologies and Global Markets 12Reportlinker Adds Biometrics: Technologies and Global Markets 13Reportlinker Adds Biometrics: Technologies and Global Markets 14Reportlinker Adds Biometrics: Technologies and Global Markets 15Reportlinker Adds Biometrics: Technologies and Global Markets 16Reportlinker Adds Biometrics: Technologies and Global Markets 17Reportlinker Adds Biometrics: Technologies and Global Markets 18Reportlinker Adds Biometrics: Technologies and Global Markets 19Reportlinker Adds Biometrics: Technologies and Global Markets 20Reportlinker Adds Biometrics: Technologies and Global Markets 21Reportlinker Adds Biometrics: Technologies and Global Markets 22High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 2High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 3New asthma research breaks the mold 2
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Medium for cryopreserving subcutaneous or omental preadipocytes...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Biology Products: